Arexvy accepted for review by the EMA to expand use in adults above 18 years

GSK has recently announced that the EMA has now accepted the company’s regulatory application to expand the use of its adjuvanted recombinant RSV vaccine to include adults from 18 years of age. Arexvy was the first RSV vaccine approved in the European Economic Area for the prevention of lower respiratory tract disease caused by RSV in adults aged 60 and older, and for those aged 50-59 years who are at increased risk for RSV disease.

Note that, RSV is a very common contagious virus affecting the lungs and breathing passages and impacts an estimated 64 million people of all ages globally every year. In addition, RSV can exacerbate certain medical conditions and further lead to severe illness resulting in hospitalisation and even death.

 

---

---

Related Topics and Keywords

arexvy, EMA, GSK, GSK’s Arexvy, rsv